News We’re Watching – Medicare Covers Dexcom CGM; New Mpox EUA; $106M Patent Verdict Against Medtronic
Executive Summary
Medicare announced coverage for the Dexcom G7 continuous glucose monitor, as well as a breast cancer indication for Natera Inc.’s Signatera; the FDA authorized a new monkeypox test; the FDA issued a warning letter to a Texas masks firm; and a new report says NIST labs are failing behind.
You may also be interested in...
Dexcom Doubles Down On Jonas Branding To Hail G7 Launch
Dexcom is commemorating the US launch of its G7 continuous glucose monitor with an expensive ad spot during the Super Bowl.
Dexcom Touts G7 As ‘The Most Accurate CGM’ As It Prepares For US Launch
The US FDA has granted authorization to Dexcom to market its G7 continuous glucose monitor, which the company will launch in the next couple of months.
News We’re Watching – FDA Mammography Update, SVB Collapse, Zoll's Data Breach, And More
News we are keeping an eye on this week includes the FDA’s first traditional market authorization for a COVID-19 test and its approval of a new neurological diagnostic. The agency also updated its device shortage list and revised mammography guidelines.